Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Cardiology

Journal Scan / Research · June 24, 2015

Safety, Tolerability, and Efficacy of Idarucizumab for the Reversal of the Anticoagulant Effect of Dabigatran in Healthy Men

The Lancet

 

Additional Info

The Lancet
Safety, Tolerability, and Efficacy of Idarucizumab for the Reversal of the Anticoagulant Effect of Dabigatran in Healthy Male Volunteers: a Randomised, Placebo-Controlled, Double-Blind Phase 1 Trial
Lancet 2015 Jun 15;[EPub Ahead of Print], S Glund, J Stangier, M Schmohl, D Gansser, S Norris, J van Ryn, B Lang, S Ramael, V Moschetti, F Gruenenfelder, P Reilly, J Kreuzer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading